Cargando…

Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?

In just a few years, immune checkpoint inhibitors have dramatically changed the landscape in oncology, offering durable responses and improved survival for many patients across several tumor types. With more than 3,300 new agents in the immuno-oncology pipeline plus a wide array of combinations bein...

Descripción completa

Detalles Bibliográficos
Autores principales: Renner, Alex, Burotto, Mauricio, Rojas, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690659/
https://www.ncbi.nlm.nih.gov/pubmed/31348737
http://dx.doi.org/10.1200/JGO.19.00142
_version_ 1783443225236733952
author Renner, Alex
Burotto, Mauricio
Rojas, Carlos
author_facet Renner, Alex
Burotto, Mauricio
Rojas, Carlos
author_sort Renner, Alex
collection PubMed
description In just a few years, immune checkpoint inhibitors have dramatically changed the landscape in oncology, offering durable responses and improved survival for many patients across several tumor types. With more than 3,300 new agents in the immuno-oncology pipeline plus a wide array of combinations being studied, it seems this new era is just getting started. These advances come with a significant caveat: most of the world population does not have access to their benefits, because the yearly cost of a novel anticancer medication can routinely exceed $100,000. There is a large amount of data showing that checkpoint inhibitors have significant activity at doses much lower than those currently approved. We review the evidence for reduced drug dosing as a strategy to increase the number of patients who can be treated and what would be needed to further validate this approach.
format Online
Article
Text
id pubmed-6690659
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-66906592019-08-15 Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy? Renner, Alex Burotto, Mauricio Rojas, Carlos J Glob Oncol Special Article In just a few years, immune checkpoint inhibitors have dramatically changed the landscape in oncology, offering durable responses and improved survival for many patients across several tumor types. With more than 3,300 new agents in the immuno-oncology pipeline plus a wide array of combinations being studied, it seems this new era is just getting started. These advances come with a significant caveat: most of the world population does not have access to their benefits, because the yearly cost of a novel anticancer medication can routinely exceed $100,000. There is a large amount of data showing that checkpoint inhibitors have significant activity at doses much lower than those currently approved. We review the evidence for reduced drug dosing as a strategy to increase the number of patients who can be treated and what would be needed to further validate this approach. American Society of Clinical Oncology 2019-07-26 /pmc/articles/PMC6690659/ /pubmed/31348737 http://dx.doi.org/10.1200/JGO.19.00142 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Special Article
Renner, Alex
Burotto, Mauricio
Rojas, Carlos
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title_full Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title_fullStr Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title_full_unstemmed Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title_short Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
title_sort immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690659/
https://www.ncbi.nlm.nih.gov/pubmed/31348737
http://dx.doi.org/10.1200/JGO.19.00142
work_keys_str_mv AT renneralex immunecheckpointinhibitordosingcanwegolowerwithoutcompromisingclinicalefficacy
AT burottomauricio immunecheckpointinhibitordosingcanwegolowerwithoutcompromisingclinicalefficacy
AT rojascarlos immunecheckpointinhibitordosingcanwegolowerwithoutcompromisingclinicalefficacy